Prospective Clinical and Biological Database for Rectal Cancer Patients at Montpellier Cancer Institute

What this Trial Is About

This research aims to create a clinical and biological database focused on rectal cancer, a subtype of colorectal cancer that represents 40% of cases. Rectal cancer has significant challenges including controlling the cancer locally and generally, and managing treatment side effects. Currently, pre-operative radiochemotherapy combined with surgery is the standard care, but this approach often leads to postoperative complications and poor functional outcomes. The study focuses on improving knowledge about rectal cancer by collecting clinical data and biological samples to assist future research and treatment development. Participants in the study will provide paraffin tissue samples from pre-treatment rectal biopsies when applicable, and blood samples collected at multiple times before any treatment and, if pre-operative radiochemotherapy is given, before surgery. Alongside this biological collection, standardized clinical data will be entered into a database. This initiative is led by the Montpellier Cancer Institute to support research on predictive markers for treatment response and disease recurrence. Participants will be involved over a period lasting up to 66 months, during which their consent rates will be tracked. The study collects tissue and blood samples to help develop new biomarkers and improve diagnostic and follow-up tests. No investigational treatments are given as part of this study. The research is observational with no blinding and includes adults aged 18 and older who receive care at the Montpellier Cancer Institute. Safety and compliance to study procedures are monitored throughout the participation.

Development of a Clinical and Biological Database in Rectum Cancer